期刊
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
卷 150, 期 -, 页码 783-795出版社
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2018.03.018
关键词
2, 4-disubstituted pyrimidines; ER alpha; VEGFR-2; Antiangiogenesis; Anti-Breast cancer
资金
- Natural Science Foundation of China (NSFC) [81373279]
Both ER alpha and VEGFR-2 are important targets for cancer therapies. Here a series of 2, 4-disubstituted pyrimidine derivatives were designed, synthesized and evaluated as dual ER alpha/VEGFR-2 ligands. Most of the derivatives exhibited potent activities in both enzymatic and cellular assays. Structure-activity relationship studies showed that a hydrogen-bonding interaction in the head section is important factors for the enhancement of ER alpha-binding affinity. The most potent compound II-90H, an analog of 2-(4-hydroxylphenyl)pyrimidine, was 19-fold more efficacious than tamoxifen in MCF-7 cancer cells and exhibited the best ERa binding affinity (IC50= 1.64 mu M) as well as excellent VEGFR-2 inhibition (IC50 = 0.085 mu M). Furthermore, this dual targeted compound II-90H exerted significantly antiestrogenic property via suppressing the expression of progesterone receptor (PgR) mRNA in MCF-7 cells and also showed obvious in vivo angiogenesis inhibitory effects in CAM assay. An induction of apoptosis and a decrease in cell migration, accompanied by transduction inhibition of Raf-1/MAPK/ERK pathway, were observed in MCF-7 cells after treatment with II-90H, suggesting that II-90H is a promising candidate for the development of multifunctional agents targeting ERa and VEGFR-2 in the therapy of some breast cancers. (C) 2018 Elsevier Masson SAS. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据